SCTC21C

SCTC21C is an investigational agent whose form is not stated in the registry developed by Sinocelltech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Pharmaceutical form: Solution for infusion； Route of administration: Subcutaneous. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07297329 (A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant), in multiple myeloma. The largest, NCT07297329, plans to enrol 292 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.